Literature DB >> 24861551

DUX4-induced gene expression is the major molecular signature in FSHD skeletal muscle.

Zizhen Yao1, Lauren Snider1, Judit Balog2, Richard J L F Lemmers2, Silvère M Van Der Maarel2, Rabi Tawil3, Stephen J Tapscott4.   

Abstract

Facioscapulohumeral dystrophy (FSHD) is caused by decreased epigenetic repression of the D4Z4 macrosatellite array and recent studies have shown that this results in the expression of low levels of the DUX4 mRNA in skeletal muscle. Several other mechanisms have been suggested for FSHD pathophysiology and it remains unknown whether DUX4 expression can account for most of the molecular changes seen in FSHD. Since DUX4 is a transcription factor, we used RNA-seq to measure gene expression in muscle cells transduced with DUX4, and in muscle cells and biopsies from control and FSHD individuals. We show that DUX4 target gene expression is the major molecular signature in FSHD muscle together with a gene expression signature consistent with an immune cell infiltration. In addition, one unaffected individual without a known FSHD-causing mutation showed the expression of DUX4 target genes. This individual has a sibling with FSHD and also without a known FSHD-causing mutation, suggesting the presence of an unidentified modifier locus for DUX4 expression and FSHD. These findings demonstrate that the expression of DUX4 accounts for the majority of the gene expression changes in FSHD skeletal muscle together with an immune cell infiltration.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24861551      PMCID: PMC4168822          DOI: 10.1093/hmg/ddu251

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

1.  High-abundance mRNAs in human muscle: comparison between young and old.

Authors:  S Welle; K Bhatt; C A Thornton
Journal:  J Appl Physiol (1985)       Date:  2000-07

2.  Expression profiling of FSHD muscle supports a defect in specific stages of myogenic differentiation.

Authors:  Sara T Winokur; Yi-Wen Chen; Peter S Masny; Jorge H Martin; Jeffrey T Ehmsen; Stephen J Tapscott; Silvere M van der Maarel; Yukiko Hayashi; Kevin M Flanigan
Journal:  Hum Mol Genet       Date:  2003-09-30       Impact factor: 6.150

Review 3.  Facioscapulohumeral dystrophy.

Authors:  Shree Pandya; Wendy M King; Rabi Tawil
Journal:  Phys Ther       Date:  2007-11-06

4.  Transcriptional profiling in facioscapulohumeral muscular dystrophy to identify candidate biomarkers.

Authors:  Fedik Rahimov; Oliver D King; Doris G Leung; Genila M Bibat; Charles P Emerson; Louis M Kunkel; Kathryn R Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-17       Impact factor: 11.205

5.  Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD.

Authors:  Yvonne D Krom; Julie Dumonceaux; Kamel Mamchaoui; Bianca den Hamer; Virginie Mariot; Elisa Negroni; Linda N Geng; Nicolas Martin; Rabi Tawil; Stephen J Tapscott; Baziel G M van Engelen; Vincent Mouly; Gillian S Butler-Browne; Silvère M van der Maarel
Journal:  Am J Pathol       Date:  2012-08-04       Impact factor: 4.307

6.  DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.

Authors:  Linda N Geng; Zizhen Yao; Lauren Snider; Abraham P Fong; Jennifer N Cech; Janet M Young; Silvere M van der Maarel; Walter L Ruzzo; Robert C Gentleman; Rabi Tawil; Stephen J Tapscott
Journal:  Dev Cell       Date:  2011-12-29       Impact factor: 12.270

7.  Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women.

Authors:  Stephen Welle; Andrew I Brooks; Joseph M Delehanty; Nancy Needler; Kirti Bhatt; Bharati Shah; Charles A Thornton
Journal:  Exp Gerontol       Date:  2004-03       Impact factor: 4.032

8.  Deregulation of the protocadherin gene FAT1 alters muscle shapes: implications for the pathogenesis of facioscapulohumeral dystrophy.

Authors:  Nathalie Caruso; Balàzs Herberth; Marc Bartoli; Francesca Puppo; Julie Dumonceaux; Angela Zimmermann; Simon Denadai; Marie Lebossé; Stephane Roche; Linda Geng; Frederique Magdinier; Shahram Attarian; Rafaelle Bernard; Flavio Maina; Nicolas Levy; Françoise Helmbacher
Journal:  PLoS Genet       Date:  2013-06-13       Impact factor: 5.917

9.  Epigenetic functions of smchd1 repress gene clusters on the inactive X chromosome and on autosomes.

Authors:  Anne-Valerie Gendrel; Y Amy Tang; Masako Suzuki; Jonathan Godwin; Tatyana B Nesterova; John M Greally; Edith Heard; Neil Brockdorff
Journal:  Mol Cell Biol       Date:  2013-06-10       Impact factor: 4.272

10.  DUX4 binding to retroelements creates promoters that are active in FSHD muscle and testis.

Authors:  Janet M Young; Jennifer L Whiddon; Zizhen Yao; Bhavatharini Kasinathan; Lauren Snider; Linda N Geng; Judit Balog; Rabi Tawil; Silvère M van der Maarel; Stephen J Tapscott
Journal:  PLoS Genet       Date:  2013-11-21       Impact factor: 5.917

View more
  101 in total

1.  Role of the Chromosome Architectural Factor SMCHD1 in X-Chromosome Inactivation, Gene Regulation, and Disease in Humans.

Authors:  Chen-Yu Wang; Harrison Brand; Natalie D Shaw; Michael E Talkowski; Jeannie T Lee
Journal:  Genetics       Date:  2019-08-16       Impact factor: 4.562

Review 2.  Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era.

Authors:  Stefania Zampatti; Luca Colantoni; Claudia Strafella; Rosaria Maria Galota; Valerio Caputo; Giulia Campoli; Giulia Pagliaroli; Stefania Carboni; Julia Mela; Cristina Peconi; Stefano Gambardella; Raffaella Cascella; Emiliano Giardina
Journal:  Neurogenetics       Date:  2019-03-25       Impact factor: 2.660

Review 3.  Facioscapulohumeral Muscular Dystrophy.

Authors:  Jeffrey M Statland; Rabi Tawil
Journal:  Continuum (Minneap Minn)       Date:  2016-12

4.  Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.

Authors:  Sujatha Jagannathan; Sean C Shadle; Rebecca Resnick; Lauren Snider; Rabi N Tawil; Silvère M van der Maarel; Robert K Bradley; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

5.  MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.

Authors:  Leo H Wang; Seth D Friedman; Dennis Shaw; Lauren Snider; Chao-Jen Wong; Chris B Budech; Sandra L Poliachik; Nancy E Gove; Leann M Lewis; Amy E Campbell; Richard J F L Lemmers; Silvère M Maarel; Stephen J Tapscott; Rabi N Tawil
Journal:  Hum Mol Genet       Date:  2019-02-01       Impact factor: 6.150

6.  FSHD1 and FSHD2 form a disease continuum.

Authors:  Sabrina Sacconi; Audrey Briand-Suleau; Marilyn Gros; Christian Baudoin; Richard J L F Lemmers; Sophie Rondeau; Nadira Lagha; Pilvi Nigumann; Chiara Cambieri; Angela Puma; Françoise Chapon; Tanya Stojkovic; Christophe Vial; Françoise Bouhour; Michelangelo Cao; Elena Pegoraro; Philippe Petiot; Anthony Behin; Bras Marc; Bruno Eymard; Andoni Echaniz-Laguna; Pascal Laforet; Leonardo Salviati; Marc Jeanpierre; Gaël Cristofari; Silvère M van der Maarel
Journal:  Neurology       Date:  2019-04-12       Impact factor: 9.910

Review 7.  Facioscapulohumeral Dystrophy.

Authors:  Leo H Wang; Rabi Tawil
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

8.  Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.

Authors:  Jonathan Oliva; Scott Galasinski; Amelia Richey; Amy E Campbell; Marvin J Meyers; Neal Modi; Jun Wen Zhong; Rabi Tawil; Stephen J Tapscott; Francis M Sverdrup
Journal:  J Pharmacol Exp Ther       Date:  2019-06-12       Impact factor: 4.030

9.  Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures.

Authors:  Jong-Won Lim; Chao-Jen Wong; Zizhen Yao; Rabi Tawil; Silvère M van der Maarel; Daniel G Miller; Stephen J Tapscott; Galina N Filippova
Journal:  Hum Mol Genet       Date:  2018-08-01       Impact factor: 6.150

10.  AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD.

Authors:  Carlee R Giesige; Lindsay M Wallace; Kristin N Heller; Jocelyn O Eidahl; Nizar Y Saad; Allison M Fowler; Nettie K Pyne; Mustafa Al-Kharsan; Afrooz Rashnonejad; Gholamhossein Amini Chermahini; Jacqueline S Domire; Diana Mukweyi; Sara E Garwick-Coppens; Susan M Guckes; K John McLaughlin; Kathrin Meyer; Louise R Rodino-Klapac; Scott Q Harper
Journal:  JCI Insight       Date:  2018-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.